The NH-BMT and Leukemia Programs are committed to publishing in the field of blood and marrow transplantation, Leukemia and hematologic malignancies. The following publications/presentations demonstrate this commitment.

ASH Oral and Poster Presentations: 2024

Collaborative Oral Presentations:

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study- Lara Stepan, BS, Sahar Ansari, PhD, Abood Okal, PhD, Justine Dell’Aringa, BS, Ethan G. Thompson, PhD, Alessandro Crotta, MD, Victor A. Chow, MD, Jeremy S. Abramson, MD, Manali Kamdar, MD, MBBS, Scott R. Solomon, MD, Patrick B. Johnston, MD, PhD, Bertram Glass, MD, Pim Mutsaers, MD, Jon E. Arnason, MD, Stephan Mielke, MD, Mazyar Shadman, MD, MPH, Francisco Hernandez-Ilizaliturri, MD, Koji Izutsu, MD, PhD, Veronika Bachanova, MD, PhD, Sami Ibrahimi, MD, Jacob Chabon, PhD, David Kurtz, MD, PhD, Ash A. Alizadeh, MD, PhD and Leanne Peiser, DPhil

Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above- Ibrahim Muhsen, MD, Anjali S. Advani, MD, Gregory W Roloff, MD, Nikeshan Jeyakumar, MD, Katharine Miller, PhD, MPH*, Amy Zhang, PhD, Katherine C. Sutherland, PA-C,, Michael R. Grunwald, MD, Vamsi K. Kota, MD, Jacob Boccucci, MD, Matthew Ulrickson, MD, Joshua Sasine, MD, Ibrahim Aldoss, MD, Tamer Othman, MD, Sumithira Vasu, MD, MBBS, Ran Reshef, MD, MSc, Marlise R. Luskin, MD, Evan C. Chen, MD, Chenyu Lin, MD, Amelia Langston, MD, Ryan D. Cassaday, MD, Noam E. Kopmar, MD, Stephanie B. Tsai, Timothy E O'Connor, MD, Talal Hilal, MD, Rawan Faramand, MD, Jae H. Park, MD, Yannis K. Valtis, MD, Melhem M. Solh, MD, Evandro Bezerra, MD, Jessica T. Leonard, MD, Simone E. Dekker, MD, PhD, Navneet Majhail, MD, MS, FASTCT, Minoo Battiwalla, MD, Shahbaz A. Malik, MD, John Mathews, MD, Paul Shaughnessy, MD, Luke Mountjoy, DO, Rasmus T. Hoeg, MD, Caspian H. Oliai, MD, Vishal Gupta, MD, Divya Koura, MD, Kaitlyn C Dykes, MD, BS, Aaron C. Logan, MD, PhD, Muthu V. Kumaran, MD, Wendy Stock, MD, Marc Schwartz, MD, Veronika Bachanova, MD, PhD, Sean Tracy, MD, PhD, Kristen M. O'Dwyer, MD, Jozal Moore, MD, Catherine J. Lee, MD, MSc, Maria Silvina Odstrcil Bobillo, MD, Noelle Frey, MD, MS, Matthew P Connor, MD52, Omer Jamy, MD, Michael Daunov, DO, Abdullah Ladha, MD, George Yaghmour, MD, Clayton Jackson, MD, Vivian Irrizary Gatell, MD, Olalekan O. Oluwole, MD, MPH, MBBS, Bhagirathbhai R. Dholaria, MBBS, Vinod Pullarkat, MD, Akil Merchant, MD, Bijal D Shah, MD, Lori Muffly, MD and LaQuisa Hill, MD

The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704- Mohamed Sorror, MD, MSc, Wael Saber, MD, MS, Brent R. Logan, PhD, Nancy Geller, PhD*, Anna Bellach, Ph.D., Jianqun Kou, MS, William A. Wood, MD, MPH9, John M. McCarty, MD, Thomas G. Knight, MD, Lyndsey Runaas, MD, Laura Johnston, MD, Jeremy Walston, Ryotaro Nakamura, MD, Asmita Mishra, MD, MBA, Joseph Uberti, MD, PhD, Parastoo B Dahi, MD, Jennifer N. Saultz, DO, Shannon R McCurdy, MD, Lawrence E Morris, MD, Philip Imus, MD, William J. Hogan, MD, Kalyan Nadiminti, MBBS, Vijaya Raj Bhatt, MD, Rebecca Olin, MD, Joseph E. Maakaron, MD, Ronald Sobecks, MD, Sarah A. Wall, MD, MPH, Deborah Mattila, BA, Bailey Protz, Steven Michael Devine, MD, Mary M. Horowitz, MD and Andrew Artz, MD, MS

Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702- Stephanie J. Lee, MD, MPH, Brent R. Logan, PhD, Mary M. Horowitz, MD, Peter Westervelt, MD, William J. Hogan, MD, Joseph A. Pidala, MD, PhD, Jason Dehn, MPH, Brandon Hayes-Lattin, MD, Nosha Farhadfar, MD, Asad Bashey, MD, PhD, Michael R. Grunwald, MD, Samer A. Srour, MD, Claudio Brunstein, MD, PhD, Heather Jill Symons, MD, Joseph Uberti, MD, PhD, Iskra Pusic, MD, Eric Leifer, PhD, Naya He, Steven Michael Devine, MD, Bronwen E. Shaw, MD, PhD and Stefan O. Ciurea, MD

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study- William G. Wierda, Kathleen Dorritie, MD, Jordan Gauthier, MD, MSc, Rajneesh Nath, MD, Thomas J. Kipps, MD, Peter A. Riedell, MD, Herbert A. Eradat, MD, Saad S. Kenderian, MD, Mohamed A. Kharfan-Dabaja, MD, MBA, Nirav N. Shah, MD, Scott R. Solomon, MD, Daniel A. Ermann, MD, Jon E. Arnason, MD, Abhinav Deol, MD, Tatyana Feldman, MD, Charalambos Andreadis, MD, MS, Monalisa Ghosh, MD, Shuo Ma, MD, PhD, Stephen J. Schuster, MD, Usama Gergis, MD, MBA, Julie M. Vose, MD, MBA, Jacob D. Soumerai, MD, Koen van Besien, MD, PhD, Sherilyn A. Tuazon, MD, Serena K. Perna, MD, San-San Ou, MS, Neha Rane, MD, Eniko Papp, PhD, Yizhe Chen, PhD and Tanya Siddiqi, MD, MBBS

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial- MHD Monzr M. Al Malki, MD, Alla Keyzner, MD, Uday Popat, MD, Yi-Bin Chen, MD, MS, Hyung C Suh, MD, PhD, Tania Jain, MD, Melhem M. Solh, MD, Anson Snow, MD, Saar Gill, MD, PhD, Lohith Gowda, MD, Joseph Uberti, MD, PhD, Erica Buonomo, PhD, Yun Wang, PhD, Nancy Nabilsi, PhD, Timothy White, Cuong Nguyen, Jim Murray, Gavin MacBeath, PhD, Chrystal Louis, MD, MPH, Shrikanta Chattopadhyay, MD, Michelle Matzko, MD, PhD and Ran Reshef, MD, MSc

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial- Ciara Louise Freeman, PhD, MSc, FRCPC, MRCP, Binod Dhakal, MBBS, Gurbakhash Kaur, MD, MA, Richard T. Maziarz, MD, Natalie Callander, MD, Adam S. Sperling, MD, PhD, Carolina Schinke, MD, Andrzej J Jakubowiak, MD, PhD, Noa Biran, MD, Douglas W Sborov, MD, Cindy Varga, MD, BSc, Abhinav Deol, MD, Abraham S. Kanate, MD, Mehmet Hakan KoçoÄŸlu, MD, Melhem M. Solh, MD, Kamalika Banerjee, MA, Rebecca Chan, MD, PhD, Myrna Nahas, MD, Ana Kostic, MD, Enrique Granados, MD, Carolyn Jackson, MD, MPH, Christopher R. Heery, MD, Tim Welliver, MD, PhD, Krina K. Patel, MD, MS and Matthew Frigault, MD, MS

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis- Sameem Abedin, MD, Qinghua Lian, Michael J Martens, PhD, MHD Monzr M. Al Malki, MD, Hany Elmariah, MD, MS, Mahasweta Gooptu, MD, Karilyn T. Larkin, MD, Brian C. Shaffer, MD, MS, Alison W Loren, MD, Melhem M. Solh, MD, Amin M. Alousi, MD, Omer Jamy, MD, Janny M. Yao, PharmD, Kristy Applegate, Miguel Angel Perales, MD, Leslie Kean, MD, Yvonne A. Efebera, MD, Ran Reshef, MD, MSc, William Clark, MD, MS, Eric Leifer, PhD, Mary M. Horowitz, MD, Richard J. Jones, MD, Javier Bolanos-Meade, MD, Shernan G. Holtan, MD and Mehdi Hamadani, MD

Program Poster Presentations:

Improved Outcomes of Adult Patients with Philadelphia-like Acute Lymphoblastic Leukemia (Ph-Like ALL) Treated within an Integrated Leukemia/Transplant Program with Incorporation of Pediatric Inspired Regimens and Early Allogeneic Transplant- Asad Bashey, MD, PhD, Xu Zhang, PhD, H. Kent Holland, MD, Lawrence E Morris, MD, Lizamarie Bachier-Rodriguez, Scott R. Solomon, MD and Melhem M. Solh, MD

Comparison of FLAG-Idarubicin to FLAG-Idarubicin Plus Venetoclax for Treatment of Newly Diagnosed AML in Patients Eligible for Intensive Induction. Analysis of 200 Consecutive Patients Treated at a Single Center- Asad Bashey, MD, PhD, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Lizamarie Bachier-Rodriguez, Scott R. Solomon, MD and Melhem M. Solh, MD

2363 Prophylactic Corticosteroids Allow Safe Outpatient Administration of Axicabtagene Ciloleucel with Comparable Toxicities to Other CAR-T Therapies in Large Cell Lymphoma- Steven Baker, MD, Asad Bashey, MD, PhD, Lizamarie Bachier-Rodriguez, Lawrence E Morris, MD, H Kent Holland, Justin Laporte, Scott R. Solomon, MD, Melissa Sanacore, PharmD and Melhem Solh, MD

3501 Intensive Conditioning with Fludarabine Plus Melphalan Versus Total Body Irradiation Prior to Haploidentical Transplant and Post-Transplant Cyclophosphamide- Scott R. Solomon, MD, Melissa Sanacore, PharmD, Asad Bashey, MD, PhD, Katelin C Jackson, Lizamarie Bachier Rodriguez, MD, Lawrence E Morris, MD, H. Kent Holland, MD and Melhem M. Solh, MD

3528 Safety and Efficacy of Ibrutinib Added to Rituximab-Based Primary Therapy of Chronic Graft-Versus-Host-Disease- Scott R. Solomon, MD, Melissa Sanacore, PharmD, Lizamarie Bachier Rodriguez, MD, Latasha McCoy*, Caitlin Guzowski, MBA, Katelin C Jackson, Xu Zhang, PhD, H. Kent Holland, MD, Lawrence E Morris, MD, Melhem M. Solh, MD and Asad Bashey, MD, PhD

4912 Extracorporeal Photopheresis (ECP) in the Era of New Chronic Graft-Versus-Disease (GVHD) Therapies- Melhem M. Solh, MD, Asad Bashey, MD, PhD, Lawrence E Morris, MD, Lizamarie Bachier-Rodriguez, H. Kent Holland, MD, Xu Zhang, PhD, Rajveer Singh, Katelin Jackson and Scott R. Solomon, MD

4913 The Degree of HLA-DPB1 Mismatch Predicted By Evolutionary Divergence Scoring Informs the Risk of Chronic Graft-Versus-Host Disease after Haploidentical Transplantation with Post-Transplant Cyclophosphamide- Melhem M. Solh, MD, Asad Bashey, MD, PhD, Michael T Aubrey, Brian Freed, Christina Roark, Lawrence E Morris, MD, H Kent Holland, Lizamarie Bachier-Rodriguez, Xu Zhang, PhD and Scott R. Solomon, MD

4948 High HLA Evolutionary Divergence in Donor HLA-B Locus Impacts Transplant Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide- Melhem M. Solh, MD, Scott R. Solomon, MD, Christina Roark, Michael T Aubrey, Lawrence E Morris, MD, H Kent Holland, Lizamarie Bachier-Rodriguez, Brian Freed and Asad Bashey, MD, PhD

Collaborative Poster Presentations:

3125 Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell- Jeremy S. Abramson, MD, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew Lunning, DO, Michael Wang, MD, Jon E. Arnason, MD, Manali Kamdar, MD, MBBS, David G. Maloney, MD, PhD, Mazyar Shadman, MD, MPH, Charalambos Andreadis, MD, MS, Alison R. Sehgal, MD, Scott R. Solomon, MD, Nilanjan Ghosh, MD, PhD, Juliana E. Hidalgo-López, MD, Jing Wang, MS, MA, Ken Ogasawara, PhD, MPH, Ashvin Singh, MBS and Tanya Siddiqi, MD, MBBS

4200 NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival- Yannis K. Valtis, MD, David Nemirovsky, Sean M. Devlin, PhD, Gregory W Roloff, MD, Ibrahim Aldoss, MD, Nikeshan Jeyakumar, MD, Katharine Miller, PhD, MPH, Amy Zhang, PhD, Katherine C. Sutherland, PA-C, Anjali S. Advani, MD, Marlise R. Luskin, MD, Evan C. Chen, MD, Omer Jamy, MD, Michael R. Grunwald, MD, Ibrahim Muhsen, MD, Noam E. Kopmar, MD, Bhagirathbhai R. Dholaria, MBBS, Simone E. Dekker, MD, PhD, Jessica T. Leonard, MD, George Yaghmour, MD, Stephanie B. Tsai, Wendy Stock, MD, Jozal Moore, MD, Kristen M. O'Dwyer, MD, Aaron C. Logan, MD, PhD, Matthew P Connor, MD, Noelle Frey, MD, MS, Evandro Bezerra, MD, Sumithira Vasu, MD, MBBS, Kaitlyn C Dykes, MD, BS, Minoo Battiwalla, MD, Chenyu Lin, MD, Matthew Ulrickson, MD, Ran Reshef, MD, MSc, Ryan D. Cassaday, MD, Laquisha C. Hill, MD, Catherine J. Lee, MD, MSc, Vamsi K. Kota, MD, Jacob Boccucci, MD, Joshua Sasine, MD, Akil Merchant, MD, Vinod Pullarkat, MD, Amelia Langston, MD, Talal Hilal, MD, Rawan Faramand, MD, Melhem M. Solh, MD, Tamer Othman, MD, Timothy E O'Connor, MD, Navneet Majhail, MD, MS, FASTCT, Shabaz Malik, MD, Luke Mountjoy, DO, Rasmus T. Hoeg, MD, Caspian H. Oliai, MD, Vishal Gupta, MD, Divya Koura, MD, Muthu V. Kumaran, MD, Marc Schwartz, MD, Veronika Bachanova, MD, PhD, Sean I. Tracy, MD, PhD, Maria Odstrcil Bobillo, MD, Abdullah Ladha, MD, Clayton Jackson, MD, Vivian Irrizary Gatell, MD, Olalekan O. Oluwole, MD, MPH, MBBS, Michael Daunov, DO, John Mathews, MD, Paul Shaughnessy, MD, Bijal D Shah, MD, Lori Muffly, MD and Jae H. Park, MD

4398 Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry- Daniel J. Landsburg, MD, Richard T. Maziarz, MD, Amy Moskop, MD, Leslie L. Popplewell, MD, MPH, Scott R. Solomon, MD, Michael T. Tees, MD, MPH, Yongzi Yu, MS, Aiesha Zia, MSc, Stephen Lim, MD, Avishek Pal, MSc, Pei Hsu, MD and Frederick Locke, MD

4633 Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004- Tanya Siddiqi, MD, MBBS, Jordan Gauthier, MD, MSc, Saad S. Kenderian, MD, Danielle M. Brander, MD, Kathleen Dorritie, MD, Jacob D. Soumerai, MD, Peter A. Riedell, MD, Nirav N. Shah, MD, Rajneesh Nath, MD, Charalambos Andreadis, MD, MS, Daniel A. Ermann, MD, Shuo Ma, MD, PhD, Tatyana Feldman, MD, Scott R. Solomon, MD, Stephen J. Schuster, MD, Sherilyn A. Tuazon, MD, Serena K. Perna, MD, San-San Ou, MS, Neha Rane, MD, Eniko Papp, PhD, Yizhe Chen, PhD and William G. Wierda

ASCO 2024 Oral and Poster Presentations: 2024

Collaborative Oral Presentations:

7013: Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study- Manali Kamdar, Scott Solomon, Jon Arnason, Patrick Johnston, Bertram Glaß, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Victor Chow, Josu Santamaria, Silvia Colicino, Ken Ogasawara, Lara Stepan, Jeremy Abramson

7016: Lisocabtagene maraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL)- Maria Lia Palomba, Tanya Siddiqi, Leo Gordon, Manali Kamdar, Matthew Lunning, Alexandre Hirayama, Jeremy Abramson, Jon Arnason, Nilanjan Ghosh, Amitkumar Mehta, Charalambos Andreadis, Scott Solomon, Ana Kostic, Ashvin Singh, Ricardo Espinola, Rashmi Bhatnagar, Anthony Raviele, Michael Wang

Program Poster Presentation:

6560: Effect of pre-transplant functional status on length of hospital stay in patients undergoing allogeneic hematopoietic stem cell transplant in an outpatient transplant program-Lizamarie Bachier-Rodriguez, Scott Solomon, Asad Bashey, Lawrence Morris, Henry Holland, Melhem Solh, Xu Zhang, Joanna Collins, Adam Drumm, Lan Lei, Catrina Kure, Briana Ford

Collaboratorive Program Poster Presentations:

TPS2678: A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation-Monzr Al Malki, Alla Keyzner, Hyung Suh, Uday Popat, Saar Gill, Yi-Bin Chen, Melhem Solh, Lohith Gowda, Erica Buonomo, Yun Wang, Jim Murray, Gavin MacBeath, Debora Barton, Shrikanta Chattopadhyay, Ran Reshef

TPS7085: Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy-Armin Ghobadi, Caron Jacobson, Joseph McGuirk, Nirali Shah, John Rossi, Tonia Buchholz, Lizamarie Bachier-Rodriguez, John Baird, Catherine Diefenbach, Umar Farooq, Francisco Hernandez-Ilizaliturri, Iris Isufi, Krish Patel, Sattva Neelapu, Craig Sauter, Jay Spiegel, Michael Tees, John Timmerman, Ginna Laport, Matthew Frank

TPS6586:A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify)-Naval Daver, Abhishek Maiti, David Sallman, Gail Roboz, Melhem Solh, Filippo Milano, Stephen Strickland, Alireza Eghtedar, Steven Kanner, Guy Ledergor, Donna Marcy, Elizabeth Garner, Brian Francica, McKay Shaw, Kalin Bird, Jennifer Rattan, Enrique Zudaire, Socorro Portella, Pankit Vachhani, Jae Park